Search PubMed⌕ Search

PubMed · 9779852

Multifocal osteonecrosis.

Abstract

OBJECTIVE: To study demographic, clinical, and radiographic staging patterns in patients with multifocal osteonecrosis to facilitate earlier diagnosis and optimize treatment. METHODS: Multifocal osteonecrosis was defined as disease of 3 or more anatomic sites. Patients were characterized demographically, which included disease associations, corticosteroid and other agent usage, presenting joints, and symptomatology. Radiographically, patients were evaluated with plain radiographs and magnetic resonance imaging (MRI) scans of all joints to determine the presenting stage of the lesions. RESULTS: We found that 32 of 1056 (3%) osteonecrosis patients under our care had multifocal disease. Associated factors included systemic lupus erythematosus (13 patients), inflammatory bowel disease (5 patients), malignancy (4 patients), and renal transplantation (3 patients). Thirty of the 32 patients (94%) had a history of corticosteroid therapy, with the other 2 patients found to have a coagulopathy. All 32 patients had bilateral femoral head involvement and 30 of 32 had bilateral knee involvement, with the other 2 having only left knee lesions. Osteonecrosis was also seen in the shoulder (28 patients), ankle (8 patients), and 3 other sites. Overall, 201 sites were involved (6.3 per patient). The majority of joints presented in a pre-collapse stage (77%). Patients most commonly presented with hip or multiple joint symptoms (22 patients, 69%). In 8 patients, the knee was the sole presenting symptomatic joint and the ankle and shoulder were the sole presenting symptomatic joints in one patient each. CONCLUSION: In patients with a diagnosis of osteonecrosis and complaints in other joints, these other areas should be fully evaluated with plain radiographs and, if inconclusive, with MRI. In patients with osteonecrosis not involving the femoral head, the patient's hips should be radiographically evaluated regardless of whether the patient is symptomatic. Patients diagnosed with osteonecrosis of the knee, shoulder, or ankle should have other joints evaluated, as such patients have multifocal disease roughly 50% of the time.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D M LaPorte, M A Mont, V Mohan, L C Jones, D S Hungerford. 1998. Multifocal osteonecrosis.. https://pubmed.ncbi.nlm.nih.gov/9779852/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗